Pharmacokinetic-Pharmacodynamic (PK-PD) Model for Tolvaptan in Patients with Hypervolemic Hyponatremia

被引：0
|
作者：
Van Wart, Scott [1 ]
Shoaf, Susan [2 ]
Mallikaarjun, Suresh [2 ]
Mager, Donald [1 ]
机构：
[1] SUNY Buffalo, Buffalo, NY 14260 USA
[2] Otsuka, Rockville, MD USA
来源：
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS | 2015年 / 42卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
W-06
引用
收藏
页码：S76 / S76
页数：1
相关论文
共 50 条
  • [41] DETERMINING THE OPTIMAL DOSE OF MOXIDECTIN FOR ONCHOCERCIASIS VIA PHARMACOKINETIC-PHARMACODYNAMIC (PK-PD) MODELLING OF DATA FROM HEALTHY VOLUNTEERS AND PATIENTS WITH ONCHOCERCIASIS
    Jamsen, Kris
    Kirkpatrick, Carl
    Opoku, Nicholas O.
    Attah, Simon K.
    Awadzi, Kwablah
    Kuesel, Annette C.
    Olliaro, Piero
    Olipoh, George
    Ryg-Cornejo, Victoria
    Tan, Beesan
    Sullivan, Mark
    Fleckenstein, Lawrence
    Rayner, Craig
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2017, 97 (05): : 238 - 239
  • [42] Pharmacokinetic-pharmacodynamic (PK-PD) correlation of ibuprofen analgesia: Comparison between ibuprofen arginate (IA) and motrin IB (MO).
    Arends, R
    Shen, D
    Desjardins, P
    Max, M
    Norwood, T
    McAuley, E
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 61 (02) : PII20 - PII20
  • [43] Effect of pharmacodynamic baseline changes in linked & indirect pharmacokinetic pharmacodynamic (pk-pd) models.
    Young, D
    Piscitelli, DA
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 59 (02) : PI103 - PI103
  • [44] Formulation of a rational dosage regimen of ceftiofur hydrochloride oily suspension by pharmacokinetic-pharmacodynamic (PK-PD) model for treatment of swine Streptococcus suis infection
    Luo, Wanhe
    Wang, Dehai
    Qin, Hua
    Chen, Dongmei
    Pan, Yuanhu
    Qu, Wei
    Huang, Lingli
    Xie, Shuyu
    JOURNAL OF VETERINARY SCIENCE, 2021, 22 (06)
  • [45] A Pharmacokinetic-Pharmacodynamic (PK-PD)-Based Treatment Strategy With Ceftriaxone (CTRX) for Acute Cholangitis That Was Proven to Be Effective in Actual Clinical Practice
    Toki, Masao
    Yamaguchi, Yasuharu
    Nakamura, Kenji
    Takahashi, Shin'ichi
    GASTROENTEROLOGY, 2011, 140 (05) : S448 - S449
  • [46] Effect of reslizumab exposure on efficacy outcomes in a pharmacokinetic-pharmacodynamic (PK-PD) analysis of weight-based intravenous (IV) dosing
    Passarell, Julie
    Jaworowicz, David
    Fiedler-Kelly, Jill
    Ludwig, Elizabeth
    Marsteller, Douglas A.
    Garin, Margaret
    Rabinovich-Guilatt, Laura
    ALLERGY AND ASTHMA PROCEEDINGS, 2019, 40 (05) : 359 - 359
  • [47] Population pharmacokinetic-pharmacodynamic (PK-PD) model of the vascular-disrupting agent 5,6-dimetifylxanthenone-4-acetic acid (DMXAA) in cancer patients.
    Li, J.
    Jameson, M. B.
    Baguley, B. C.
    Pili, R.
    Baker, S. D.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 : S3 - S3
  • [48] Population pharmacokinetic-pharmacodynamic (PK-PD) model of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in cancer patients.
    Li, J.
    Jameson, M. B.
    Baguley, B. C.
    Pili, R.
    Baker, S. D.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 : S6 - S6
  • [49] A new pharmacokinetic/pharmacodynamic model (PK/PD) for mivacurium
    Laurin, J
    Nekka, F
    Donati, F
    Varin, F
    ANESTHESIOLOGY, 1996, 85 (3A) : A323 - A323
  • [50] Colistin PK-PD (pharmacokinetic-pharmacodynamics) in Indian patients
    Gautam, V.
    Sharma, M.
    Shafiq, N.
    Mouton, J. W.
    Malhotra, S.
    Ray, P.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2016, 45 : 125 - 126
12345